NeuRank: learning to rank with neural networks for drug–target interaction prediction
Abstract Background Experimental verification of a drug discovery process is expensive and time-consuming. Therefore, recently, the demand to more efficiently and effectively identify drug–target interactions (DTIs) has intensified. Results We treat the prediction of DTIs as a ranking problem and pr...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMC
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/45ca5360d403433b8f68378e784b6a64 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Abstract Background Experimental verification of a drug discovery process is expensive and time-consuming. Therefore, recently, the demand to more efficiently and effectively identify drug–target interactions (DTIs) has intensified. Results We treat the prediction of DTIs as a ranking problem and propose a neural network architecture, NeuRank, to address it. Also, we assume that similar drug compounds are likely to interact with similar target proteins. Thus, in our model, we add drug and target similarities, which are very effective at improving the prediction of DTIs. Then, we develop NeuRank from a point-wise to a pair-wise, and further to list-wise model. Conclusion Finally, results from extensive experiments on five public data sets (DrugBank, Enzymes, Ion Channels, G-Protein-Coupled Receptors, and Nuclear Receptors) show that, in identifying DTIs, our models achieve better performance than other state-of-the-art methods. |
|---|